Comparisons of patient self-report, neurologic examination, and functional impairment in MSE.L.J. Hoogervorst, Chris H. Polman, L.M.L. van Winsen et al.|Neurology|2001Cited by 86
The patient's perception of a (reliable) change in the Multiple Sclerosis Functional C ompositeE.L.J. Hoogervorst, Chris H. Polman, Nynke F. Kalkers et al.|Multiple Sclerosis Journal|2004Cited by 57
Personalized extended interval dosing of natalizumab in MSZoé L. E. van Kempen, Joep Killestein, E.L.J. Hoogervorst et al.|Neurology|2020Cited by 56
A Study Validating Changes in the Multiple Sclerosis Functional CompositeE.L.J. Hoogervorst, Chris H. Polman, Nynke F. Kalkers et al.|Archives of Neurology|2002Cited by 46
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple SclerosisEline M. E. Coerver, Eva Strijbis, Joep Killestein et al.|JAMA Neurology|2024Cited by 29